Larimar Therapeutics, Inc.

LRMR · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$47,712-$26,182-$29,281-$28,824
Dep. & Amort.$88$87-$667$77
Deferred Tax$0$0$0$0
Stock-Based Comp.$1,785$1,828$1,834$2,410
Change in WC$17,480$5,420$1,634$5,761
Other Non-Cash-$394-$534-$60-$1,239
Operating Cash Flow-$28,753-$19,381-$26,540-$21,815
Investing Activities
PP&E Inv.-$23-$19-$49-$179
Net Acquisitions$0$0$0$0
Inv. Purchases-$3,458-$27,639-$52,503-$38,624
Inv. Sales/Matur.$36,500$46,500$67,000$58,000
Other Inv. Act.$0$0$0$0
Investing Cash Flow$33,019$18,842$14,448$19,197
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$65,287$0$0$36
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$65,287$0$0$36
Forex Effect$0$0$0$0
Net Chg. in Cash$69,553-$539-$12,092-$2,582
Supplemental Information
Beg. Cash$21,193$21,732$33,824$36,406
End Cash$90,746$21,193$21,732$33,824
Free Cash Flow-$28,776-$19,400-$26,589-$21,994